ABT
Abbott Laboratories Healthcare - Medical Devices Investor Relations →
Abbott Laboratories (ABT) closed at $88.41 as of 2026-06-19, trading 18.5% below its 200-week moving average of $108.45. This places ABT in the extreme value zone. The stock moved further from the line this week, up from -18.7% last week. With a 14-week RSI of 24, ABT is in oversold territory.
Trading volume is running at 1.4x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.03 ratio) is neutral — neither side is clearly dominating.
Over the past 2365 weeks of data, ABT has crossed below its 200-week moving average 26 times. On average, these episodes lasted 9 weeks. Historically, investors who bought ABT at the start of these episodes saw an average one-year return of +21.1%.
With a market cap of $154.0 billion, ABT is a large-cap stock. The company generates a free cash flow yield of 4.1%. Return on equity stands at 12.3%. The stock trades at 3.0x book value.
ABT is a Dividend Aristocrat, having increased its dividend for 25 or more consecutive years.
Over the past 33.5 years, a hypothetical investment of $100 in ABT would have grown to $3221, compared to $3097 for the S&P 500. That represents an annualized return of 10.9% vs 10.8% for the index — confirming ABT as a market-beating investment and the kind of quality company where buying during 200-week moving average touches has historically been rewarded.
In the past 12 months, corporate insiders have made 4 open-market purchases totaling $4,229,135. Notably, these purchases occurred while ABT is trading below its 200-week moving average — insiders are buying when the market is most pessimistic.
Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: ABT vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After ABT Crosses Below the Line?
Across 25 historical episodes, buying ABT when it crossed below its 200-week moving average produced an average return of +19.2% after 12 months (median +19.0%), compared to +17.3% for the S&P 500 over the same periods. 91% of those episodes were profitable after one year. After 24 months, the average return was +40.3% vs +35.0% for the index.
Each line shows $100 invested at the moment ABT crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Bean Score Experimental
The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices ABT would reach each dislocation threshold.
Dislocation Price Levels
Prices where ABT's Bean Score would hit each σ threshold. Valid until next earnings report: 2026-07-16.
| Level | σ | Price | Signal |
|---|---|---|---|
| Deep Value | +2σ | $82.95 | Unusually cheap — potential buy zone |
| Value | +1σ | $87.14 | Cheap vs. own history |
| Fair Value | +0σ | $91.77 | Historical mean behavior |
| Expensive | -1σ | $96.93 | Expensive vs. own history |
| Deep Expensive | -2σ | $102.69 | Unusually expensive — potential trim zone |
Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end
Signal Accuracy Collecting Data
The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"
Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are reference points for identifying potential swing trade opportunities, not buy/sell signals. FCF values update quarterly with earnings; between reports, all movement is price-driven.
Dislocation Scores Experimental
Each score measures deviation from ABT's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.
Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.
Historical Touches
ABT has crossed below its 200-week MA 26 times with an average 1-year return of +21.1% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Aug 1981 | Sep 1981 | 4 | 6.7% | +51.0% | +36723.2% |
| Aug 1993 | Aug 1993 | 1 | 0.1% | +22.4% | +3541.6% |
| Jan 2000 | Mar 2000 | 10 | 11.1% | +43.8% | +1127.6% |
| Jun 2002 | Nov 2002 | 21 | 27.4% | +27.2% | +902.5% |
| Nov 2002 | May 2003 | 23 | 18.7% | +3.4% | +730.8% |
| May 2003 | May 2003 | 1 | 1.5% | +11.6% | +754.0% |
| Jul 2003 | Sep 2003 | 8 | 9.7% | +10.4% | +763.1% |
| Sep 2003 | Nov 2003 | 7 | 3.3% | +17.7% | +744.4% |
| Jan 2004 | Feb 2004 | 3 | 1.2% | +25.8% | +721.4% |
| Feb 2004 | Apr 2004 | 8 | 8.3% | +25.9% | +714.4% |
| Feb 2009 | Sep 2009 | 31 | 12.9% | +18.5% | +473.3% |
| May 2010 | Jul 2010 | 11 | 5.7% | +11.8% | +434.3% |
| Nov 2010 | Mar 2011 | 20 | 6.5% | +16.5% | +426.6% |
| Feb 2016 | Feb 2016 | 2 | 1.4% | +17.3% | +186.7% |
| May 2016 | May 2016 | 3 | 1.8% | +20.5% | +180.8% |
| Jun 2016 | Jun 2016 | 3 | 2.8% | +26.3% | +177.7% |
| Oct 2016 | Nov 2016 | 1 | 0.4% | +45.2% | +169.4% |
| Nov 2016 | Jan 2017 | 6 | 3.8% | +46.7% | +168.9% |
| Sep 2022 | Oct 2022 | 1 | 2.6% | +2.0% | -1.6% |
| Oct 2022 | Nov 2022 | 3 | 4.3% | +3.8% | -0.3% |
| Feb 2023 | Apr 2023 | 6 | 5.5% | +21.3% | -6.1% |
| May 2023 | Jun 2023 | 3 | 2.0% | +3.1% | -8.7% |
| Aug 2023 | Dec 2023 | 17 | 13.9% | +9.3% | -9.9% |
| Apr 2024 | Jul 2024 | 15 | 5.8% | +24.0% | -14.2% |
| Jan 2026 | Feb 2026 | 2 | 2.1% | N/A | -17.2% |
| Mar 2026 | Ongoing | 16+ | 22.6% | Ongoing | -18.8% |
| Average | 9 | — | +21.1% | — |
Frequently Asked Questions
Is ABT below its 200-week moving average?
Yes. As of 2026-06-19, Abbott Laboratories (ABT) is trading 18.5% below its 200-week moving average of $108.45. The current price is $88.41.
What is ABT's 200-week moving average price?
Abbott Laboratories's 200-week moving average is $108.45 as of 2026-06-19. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when ABT drops below its 200-week moving average?
ABT has crossed below its 200-week moving average 26 times in our data. On average, buying at that moment produced a one-year return of +21.1%. These dips have historically been decent entry points. These episodes lasted 9 weeks on average.
Is ABT a good value right now?
Here's what our data says about ABT as of 2026-06-19: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 24 (oversold). Free cash flow yield is 4.1%. Return on equity is 12.3%. Price-to-book is 3.0x. This is not a buy or sell recommendation — always do your own research.
How does ABT compare to the S&P 500?
Over the past 33.5 years, $100 invested in ABT would have grown to $3221, compared to $3097 for the S&P 500. That's 10.9% annualized vs 10.8% for the index. ABT has outperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-06-19